We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+6.29%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$109B
AUM Growth
+$10.4B
Cap. Flow
-$1.13B
Cap. Flow %
-1.03%
Top 10 Hldgs %
18.72%
Holding
8,634
New
1,446
Increased
2,646
Reduced
3,048
Closed
1,267

Sector Composition

Rank Sector Weight
1 Technology 7.07%
2 Consumer Discretionary 5.88%
3 Financials 5.83%
4 Industrials 4.49%
5 Healthcare 4.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PLAG icon
7176
Planet Green Holdings
PLAG
$16.1M
$7K ﹤0.01%
49
-106
-68% -$15.4K
CYTR
7177
PUT
DELISTED
CytRx Corp
CYTR
$7K ﹤0.01%
+2,500
New +$6.33K
RTK
7178
DELISTED
Rentech, Inc.
RTK
$7K ﹤0.01%
13,345
-4,362
-25% -$7.03K
GMO
7179
DELISTED
General Moly, Inc.
GMO
$6K ﹤0.01%
12,971
-41,259
-76% -$19.8K
AVEO
7180
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$6K ﹤0.01%
+1,098
New +$7.93K
ANTH
7181
CALL
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$6K ﹤0.01%
1,850
-638
-26% -$3.02K
ANTH
7182
PUT
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$6K ﹤0.01%
1,875
-1,063
-36% -$5.03K
CYTR
7183
DELISTED
CytRx Corp
CYTR
$6K ﹤0.01%
+2,121
New +$5.37K
ARGS
7184
CALL
DELISTED
Argos Therapeutics, Inc.
ARGS
$6K ﹤0.01%
640
-390
-38% -$24.7K
KMI.WS
7185
DELISTED
Kinder Morgan Inc
KMI.WS
$6K ﹤0.01%
2,711,056
+1,655,882
+157% +$7.12K
IMNN icon
7186
CALL
Imunon
IMNN
$6.64M
$5K ﹤0.01%
+6
New +$5.16K
PED icon
7187
PEDEVCO
PED
$160M
$5K ﹤0.01%
+268
New +$5.67K
ANTH
7188
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5K ﹤0.01%
1,498
-28,176
-95% -$133K
GLOWE
7189
DELISTED
GLOWPOINT INC
GLOWE
$3K ﹤0.01%
10,315
-102,239
-91% -$29.7K
SVRA icon
7190
CALL
Savara
SVRA
$1.08B
$1K ﹤0.01%
171
-53
-24% -$457
ABCB icon
7191
Ameris Bancorp
ABCB
$6B
-21,831
Closed -$952K
ABEO icon
7192
CALL
Abeona Therapeutics
ABEO
$361M
-432
Closed -$52K
ABEO icon
7193
Abeona Therapeutics
ABEO
$361M
-654
Closed -$79K
ABG icon
7194
CALL
Asbury Automotive
ABG
$3.78B
-4,100
Closed -$253K
ABG icon
7195
PUT
Asbury Automotive
ABG
$3.78B
-4,500
Closed -$278K
ABUS icon
7196
PUT
Arbutus Biopharma
ABUS
$906M
-37,500
Closed -$92K
ACGL icon
7197
CALL
Arch Capital
ACGL
$33.5B
-9,000
Closed -$259K
ACGL icon
7198
PUT
Arch Capital
ACGL
$33.5B
-14,700
Closed -$423K
ACWV icon
7199
iShares MSCI Global Min Vol Factor ETF
ACWV
$3.38B
-51,459
Closed -$3.74M
ACWX icon
7200
iShares MSCI ACWI ex US ETF
ACWX
$12B
-103,940
Closed -$4.19M

Similar funds

Citadel Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Citadel Advisors held 8,634 positions worth $109B, up 11% from $99B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Citadel Advisors's Q1 2017 filing shows 1,446 new, 2,646 increased, 3,048 reduced and 1,267 closed positions. Its largest new stake was Meta Platforms (Facebook): 4,289,917 shares worth $609M. The largest sale was Alphabet (Google) Class A, an estimated $482M.

By sector, the portfolio is most concentrated in Technology at 7.1% of assets, up from 5.3% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Citadel Advisors's largest Q1 2017 buy was Meta Platforms (Facebook): 4,289,917 shares worth $609M.
  • Citadel Advisors added most to Microsoft in Q1 2017, an estimated $529M increase.
  • Citadel Advisors's biggest Q1 2017 reduction was Alphabet (Google) Class A, cutting an estimated $482M.
  • Citadel Advisors fully exited Celgene Corp in Q1 2017, selling an estimated $341M.
  • Citadel Advisors's ten largest holdings make up 19% of its $109B portfolio in Q1 2017.
  • Citadel Advisors opened 1,446 new positions and closed 1,267 in Q1 2017.
  • Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $109B.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.